


2Q 2024 Financial Results

REVENUE
\$207.1M
ORGANIC REVENUE GROWTH
3.6%
ADJUSTED EBITDA
\$48.8M
ADJUSTED EPS
\$0.10


"Our second quarter results were in-line with our expectations. Both segments delivered steady top-line growth and strong Adjusted EBITDA margin expansion during the quarter."

Thomas Logan,
Chief Executive Officer

QUARTER HIGHLIGHTS
Organic revenue growth in-line with expectations, led by Technologies segment

Total company organic revenue growth of 3.6% (Medical +2.7%, Technologies +4.1%)

Signed 20-year strategic nuclear new build partnership agreement with EDF

Fortifies Mirion's competitive positioning in the nuclear new build market in the decades to come

Completed redemption of all outstanding public and private warrants and refinanced debt


2024 Financial Outlook * Updated

REVENUE GROWTH
5%-7%
ORGANIC REVENUE GROWTH
4%-6%
ADJUSTED EBITDA*
\$195M-\$205M
ADJUSTED FREE CASH FLOW
\$65M-\$85M

Mirion announced Q2 2024 financial results on August 1, 2024. Full results, reconciliations and forward-looking statements available in the [earnings press release](#) and [earnings presentation](#).

- Adjusted EBITDA is a non-GAAP measure presented for supplemental informational purposes. A reconciliation of Adjusted EBITDA is available in our Q2 2024 Earnings Presentation.
- Adjusted EPS is a non-GAAP measure presented for supplemental informational purposes. A reconciliation of Adjusted EPS is available in our Q2 2024 Earnings Presentation.
- Adjusted Free Cash Flow is a non-GAAP measure presented for supplemental informational purposes. A reconciliation of Adjusted Free Cash Flow is available in our Q2 2024 Earnings Presentation.